Incentives to Collaborate: reversing productivity declines in drug development through open science

Description

Efforts by governments, firms, and patients to deliver pioneering drugs for critical health needs face the challenge of diminishing efficiency in developing those medicines. Despite improvements in reducing failure rates in drug development, the costs of developing new drugs continue to increase. While multi-sectoral collaborations involving firms, researchers, patients, and policymakers are widely recognized as crucial for countering this decline, existing incentives to engage in drug development do little to stimulate collaborative innovation.

In this presentation, we examine how to structure collaborations to meet the scientific needs of the team, to contribute knowledge openly to the larger scientific community, and to provide incentives that maximize both. We examine, for example, the relative benefits of regulatory exclusivities over patents in collaborative settings and how governments can make those exclusivities more attractive. We also look at how students, junior scientists and lab directors can more easily participate in these collaborations and share knowledge.

Speakers

Jacqueline Sullivan, Department of Philosophy, Rotman Institute of Philosophy, Western Institute for Neuroscience, Western University, Canada

E. Richard Gold, Faculty of Law and Faculty of Medicine and Health Sciences, McGill University, Canada